SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Themis Medicare gets DCGI nod for antiviral drug ‘Viralex’

21 Mar 2022 Evaluate

Themis Medicare has received approval for its antiviral drug ‘Viralex’ from the Drug Controller General of India (DCGI). As per the results of a double-blind randomized controlled trials (RCT), the drug helps in early relief of the clinical symptoms in mild to moderate COV1D- 19 patients.

In line with the DCGI's current approach for approval of medicines for the management of the ongoing pandemic, approval for Viralex (Generic name: lnosine pranobex) is based on the results of the robust phase 2 and phase 3 RCTs conducted in India, and the well-established safety profile of the drug.

As per the results of the Phase 3 Randomized, Double-blind, Placebo-controlled Trial, 80.17% of patients treated with Viralex showed clinical improvement on day 6, which is significantly higher (p<0.001) from that in the controlled group (52.38%) among the mild to moderate non-hospitalized COVID-19 patients. Clinical Cure (complete relief from symptoms) was also seen in significantly higher number of patients in the Viralex group as compared to that in the placebo group on day 6 of treatment. There was early improvement and complete relief from symptoms in patients who received Viralex. This drug was well tolerated by the patients without any serious side effects. The study was conducted during the Delta wave of the pandemic.

Themis Medicare is a research-based pharmaceutical company specializing in manufacture of a wide range of products for application areas like Pain Management, Critical Care and Anti-Infectives.

Themis Medicare Share Price

90.25 4.97 (5.83%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×